GlassScriptPhysician profile
Ziad C Boujaoude
NPI 1619954286
$1,017.09
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $45.98 · 2021: $50.07 · 2022: $77.28 · 2023: $180 · 2024: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $363.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $160.68 | 2019 | |
| Boston Scientific Corporation | $123.65 | 2023 | |
| Intuitive Surgical, INC. | $111.71 | 2022-2023 | |
| Inspire Medical Systems, INC. | $97.04 | 2024 | Inspire |
| Pinnacle Biologics, INC | $85.95 | 2024 | Photofrin |
| Olympus America INC. | $80.13 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $64.31 | 2019 | |
| Glaxosmithkline, LLC. | $63.95 | 2019 | |
| Philips North America LLC | $63.20 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $28.87 | 2019 | |
| Mylan Specialty L.P. | $27.83 | 2019-2020 | |
| Olympus Corporation of The Americas | $25.76 | 2019 | |
| Genentech USA, INC. | $18.66 | 2019 | |
| Erbe USA INC | $15.05 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.52 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.40 | 2019 | |
| Veran Medical Technologies, INC. | $9.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ziad Boujaoude listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.